Gene therapy hope for kids with cystinosis: new trial opens

NCT ID NCT06910813

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 22 times

Summary

This study tests a new gene therapy called DFT383 in children aged 2 to 5 with nephropathic cystinosis, a rare disease that damages the kidneys and other organs. The treatment aims to fix the genetic problem and reduce the need for current medications. About 30 children will take part, with some receiving the therapy and others serving as a comparison group.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEPHROPATHIC CYSTINOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

Locations

  • Baylor College of Medicine - Texas Children's Hospital (recuiting Cohort 0)

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Emory University School of Medicine - Children's Healthcare of Atlanta (recuiting Cohort 0)

    RECRUITING

    Atlanta, Georgia, 30322, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Stanford University - Stanford Children's Health

    RECRUITING

    Stanford, California, 94305, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of California at San Diego - Rady Children's Hospital

    RECRUITING

    San Diego, California, 92123, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.